替比夫定与恩替卡韦治疗Peg-IFNα-2a不应答的血清HBeAg阳性的慢性乙型肝炎患者效果分析

doi:10.3969/j.issn.1672-5069.2018.02.032

Abstract

Zhang Chenxi, Li Shaohao. Application of telbivudine and entecavir in treatment of patients with serum HBeAg-positive hepatitis B who failed to response to Peg-IFN α-2a therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 281-282.

References

[1] Keating GM.Entecavir:a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs,2011,71(18):2511-2529.
[2] Liaw YF,Sheen IS,Lee CM,et al.Tenofovir disoproxil fumarate (TDF),emtricitabine/TDF,and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology,2011,53(1):62-72.
[3] Lee Y,Hao B.Nuclear syndrome similar immunity adjustment improvement of Kuji treatment type hepatitis B research progress. Liver,2016,21(9):778-780.
[4] Papatheodoridis GV,Chan HL,Hansen BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy. J Hepatol,2015,62(4):956-967.
[5] Li HJ,Wu S,Zhang LY,et al.Clinical analysis of entecavir in the treatment of HBeAg-positive chronic hepatitis B. J Syst Med,2017,27(3) 33-35.
[6] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[7] Seto WK,Hui AJ,Wong VW, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study. Gut,2015,64(4):667-667.
[8] 王秀珍,刘雪峰,张长. 干扰素α序贯替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效及安全性. 中国生化药物杂志,2016,12(2):164-166.
[9] 张亚萍,张岭漪,于尚睿,等. HBeAg阳性慢性乙型肝炎的抗病毒治疗研究进展. 中国医学创新,2017,8(4):143-149.
[10] Liaw YF,Raptopoulou M,Cheinquer H,et al.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation:a randomized,open-label study.Hepatology,2011,54(1):91-100.
[11] Cai S,Yu T,Jiang Y,et al.Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med,2016,16(3):429-436.
[12] Wei MJ,Pan XN,Wei KP,et al.Efficacy of HBV-pulsed DCS in combination with entecavir in patients with chronic hepatitis B infection. Int Immunop,2015,27(2):238-243.
[13] Kim HS,Yim HJ,Jang MK,et al.Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J gastroenterol,2015,21(38):108-114.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.

Application of telbivudine and entecavir in treatment of patients with serum HBeAg-positive hepatitis B who failed to response to Peg-IFN α-2a therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments